Results 41 to 50 of about 19,663 (194)

The structures of (S)-crizotinib (A) and (R)-crizotinib (B).

, 2015
The structures of (S)-crizotinib (A) and (R)-crizotinib (B).
Qifeng Bai (220551), Dabo Pan (630785), Huanxiang Liu (418534), Yuzhen Niu (709953), Danfeng Shi (838463), Xiaojun Yao (220558)   +5 more
core   +1 more source

Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro

Frontiers in Oncology, 2020
We investigated possible conditions or drugs that could target P-glycoprotein (P-gp)-overexpressing drug-resistant KBV20C cancer cells. Specifically, we focused on identifying a single treatment with a relatively low half maximal inhibitory concentration
Kyeong Seok Kim, Chunxue Jiang, Ji Young Kim, Jae Hyeon Park, Hae Ri Kim, Su Hyun Lee, Hyung Sik Kim, Sungpil Yoon   +7 more
doaj   +1 more source

Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

OncoImmunology, 2021
Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual ...
Adriana Petrazzuolo, Maria Perez-Lanzon, Peng Liu, M. Chiara Maiuri, Guido Kroemer   +4 more
doaj   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer

, 2013
BACKGROUND: In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK ) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.
Crinó, Lucio, Jänne, Pasi A., Thomas, Michael, Solomon, Benjamin J., Kim, Dong Wan, Wu, Yi Long, Wilner, Keith D., Moro-Sibilot, Denis, O'Byrne, Kenneth J., Polli, Anna, Riely, Gregory J., Camidge, D. Ross, Besse, Benjamin, Kim, Dong-Wan, Wu, Yi-Long, Iyer, Shrividya, Ahn, Myung-Ju, Hirsh, Vera, Seto, Takashi, Blackhall, Fiona, De Pas, Tommaso, O'Byrne, Kenneth J., Wu, Yi- Long, Nakagawa, Kazuhiko, Mok, Tony, Shaw, Alice T., Ahn, Myung Ju, Blackhall, Fiona; id_orcid, Jaenne, Pasi A., Tassell, Vanessa   +29 more
core   +1 more source

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source

Crizotinib: Renal Safety Evaluation

, 2017
Anaplastic lymphoma kinase 1 (ALK 1) is a member of the insulin receptor tyrosine kinase family. Crizotinib is a small molecule inhibitor available for clinical use, which is found within the ALK family of drugs.
Mark A. Perazella, Hassan Izzedine
core   +1 more source

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

, 2021
International audienceBackground: The AcSé-crizotinib program provides extensive screening of crizotinib-targeted genomic alteration in several malignancies.
Johnson, Laetitia, Meriaux, Emeline, Colignon, Nikias, Gratet, Alain, Lecomte, Thierry, Mary, Florence, Haineaux, Paul-Arthur, Menu, Yves, Plaza, Jérome, Guimbaud, Rosine, Legrand, Frédéric, Mineur, Laurent, Samalin, Emmanuelle, de La Fouchardière, Christelle, Aparicio, Thomas, Gomez-Roca, Carlos, Vassal, Gilles, Selves, Jannick, Cozic, Nathalie   +18 more
core   +1 more source

Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report

Case Reports in Oncology, 2022
Rapid tumor growth after cessation of molecularly targeted drugs, called “disease flare,” may occur and affect the prognosis of lung cancer. However, this phenomenon has never been reported in ROS proto-oncogene 1 (ROS1) fusion-positive lung ...
Yosuke Amano, Hidenori Kage, Goh Tanaka, Yusuke Sato, Mariko Tanaka, Takahide Nagase   +5 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source